Slide 1: Corporate Overview
Corporate Overview July 2026 NASDAQ: LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Lantern's AI platforms are transforming the cost, pace, and timeline of cancer drug discovery
Lantern’s AI platforms are transforming the cost, pace, and timeline of cancer drug discovery and development AI insights and Lantern can compress the biomarkers can increase timeline of early-stage drug the odds of clinical trial development by 70% and success by 12X* reduce the cost by 80% (*Parke
Slide 4: Lantern's AI-Driven Business Model has Multiple Routes Towards Success
Lantern’s AI-Driven Business Model has Multiple Routes Towards Success Areas of Focus Successes to Date High-value 1 Rescue & Based on previous clinical data Partnering and observations, LP-300 was Targeted & Licensing Reposition rescued for never smokers with Clinical Trials Opportunities Drug Cand
Slide 5: Lantern's Diverse & Unique AI Driven Pipeline of Drug Programs
Lantern’s Diverse & Unique AI Driven Pipeline of Drug Programs Lantern has 10 disclosed drug programs including the Phase 2 HarmonicTM trial Lantern Pharma (NASDAQ: LTRN) Program Indication Preclinical Phase 1a Phase 1b Phase II Non-Small Cell Lung Cancer for Never Smokers LP-300 Market Potential: $
Slide 6: Clinical Trials Planned for STAR-001
CLINICAL TRIALS PLANNED FOR STAR-001 NASDAQ: LTRN 5
Slide 7: Twelve FDA Designations Demonstrate our Data-driven, AI-enabled Approach
Twelve FDA Designations Demonstrate our Data-driven, AI-enabled Approach to Transform Drug Development & Strengthen Commercial Value Drug Annual US Designation Disease Indication Candidate Population LP-184 Glioblastoma 10,525 Fast Track Designation LP-184 Triple Negative Breast Cancer 43,000 LP-184
Slide 8: AI-Powered RADR Modules for Oncology
A proprietary integrated experimental biology, oncology-focused, machine-learning-based drug development platform AI-Powered RADR® Modules for Oncology 200+ 80%+ Billion Prediction * Success Drug Discovery and Development Discover mechanism Characterize specialized m1 of action m5 attributes of a mo
Slide 9: Lantern Pharma is a Top 10 End-to-End AI Drug Discovery Company
Lantern Pharma is a Top 10 End-to-End AI Drug Discovery Company According to Deep Pharma Intelligence NASDAQ: LTRN 8
Slide 10: PredictBBB - Predict any molecule's brain permeability
PredictBBB - Predict any molecule’s brain permeability The Challenge Less than 6% of molecules cross the Blood Brain Barrier (BBB) - one of pharmaceutical development's most persistent challenges The Solution predictbbb.ai PredictBBB™ uses AI to predict whether a molecule can cross the BBB - instant
Slide 11: From Prediction to Understanding
PredictBBB - Moving beyond permeability prediction to multi-dimensional molecular insight From Prediction to Understanding PredictBBB™ now extends beyond binary BBB prediction to provide deep molecular analysis across key dimensions of drug design Multi-Dimensional Molecular Intelligence Overview In
Slide 12: withZeta.ai – The Multi-Agentic Co-Scientist & AI System
withZeta.ai – The Multi-Agentic Co-Scientist & AI System For Rare Cancer Drug Development and Research withZeta addresses the fundamental challenge in rare cancer research and drug development where critical insights are scattered across disconnected data sources. Our platform integrates curated dat
Slide 13: withZeta.ai Roadmap
withZeta.ai Roadmap - Multi-agent reasoning, computational biology, and enterprise infrastructure powering the next generation of oncology AI withZeta.ai is evolving into a unified AI research environment combining multi-agent reasoning, computational biology, and enterprise-grade scientific infrast
Slide 14: Research and Clinical Collaborations
Research and Clinical Collaborations Strategic collaborations that are providing unique real-world insights and accelerating timelines World-Class Academic and Research Institutions Biopharma Collaborations NASDAQ: LTRN 13
Slide 15: LP-300 for the Treatment of NSCLC in Never Smokers
LP-300 for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Never Smokers Relapsed NSCLC for Never Smokers Lead Indication with L858R Mutation Clinical Status Phase 2 (USA, Taiwan, Japan) Market Potential* $3.5-4+ billion Indication Size* 150,000 + Cases Target/ MOA Tyrosine Kinases & Cell Red
Slide 16: Mechanism of Action – LP-300
Mechanism of Action – LP-300 LP-300’s multimodal MoA resensitizes NSCLC to chemo in the never smoker population Relevant Receptor Signaling LP-300’s multimodal MoA resensitizes NSCLC to chemo Pathways in Never Smokers 1 LP-300 Directly Engages with TKI Receptors via Cysteine Modification A B C D A-B
Slide 17: Clinical Trial – The Harmonic Phase 2 Trial for LP-300
Clinical Trial – The HarmonicTM Phase 2 Trial for LP-300 Accelerating recruitment efforts for a growing indication with limited treatment options NCT05456256 ~60 Trial Highlights • Completed Japanese patient cohort enrollment ahead of Multi-national Phase 2 Trial with 6 sites in the US, 5 schedule a
Slide 18: Target Lesion Decreased in Over 70% of Evaluable L858R Patients
Target Lesion Decreased in Over 70% of Evaluable L858R Patients Percent change in cancer lesion size over time Percent change in cancer lesion size by patient Protocol Amendments following FDA Type C Interaction 1 Focus enrollment EGFR Exon 21 L858R patients 2 Convert design Migrate to Phase 2 singl
Slide 19: LP-300 Shows Deep Tumor Responses in Patients with EGFR L858R–Mutated NSCLC
LP-300 Shows Deep Tumor Responses in Patients with EGFR L858R–Mutated NSCLC As of 11 May, 2026 Disease Control Rate = 87%* PFS > 12 months Observed in 3 Patients ** * ** *one patient excluded from the bar graph: brain lesion identified post-randomization, before the scheduled protocol specified tumo
Slide 20: LP-184 for the Treatment of Advanced Solid Tumors
LP-184 for the Treatment of Advanced Solid Tumors Lead Indications DDR deficient solid tumors including TNBC, Bladder Cancer, Clinical Status Multiple Phase 1b/2 trials planned Market Potential* $10+ Billion Indication Size* 170,000 + Cases, Estimated 400,000 + Cases Global Target/ MOA Double-strand
Slide 21: Disease Overview – Advanced Solid Tumors with DDR Deficiencies
Disease Overview – Advanced Solid Tumors with DDR Deficiencies LP-184 has Blockbuster Potential Across Multiple Cancers as a Single Agent or in Combination Therapy Annual US Market Potential: $10+ Billion (DDR Deficient Solid Tumors) Advanced Solid Tumors 1 in 4 people have solid • Advanced solid tu
Slide 22: LP-184's MoA was Predicted by RADR and Validated in Multiple Lab Studies
LP-184’s MoA was Predicted by RADR® and Validated in Multiple Lab Studies In silico In vitro Using RADR®, PTGR1 was Identified as a Validated using Biomarker that Predicts LP-184 Response CRISPR Experiments A. B. C. • Prostaglandin Reductase 1 (PTGR1) is an oxidoreductase enzyme • CRISPR-mediated de
Slide 23: LP-184 Treatment Results in Complete Regression in Multiple DDR Deficient PDX Models
LP-184 Treatment Results in Complete Regression in Multiple DDR Deficient PDX Models In-vitro PDX pancreatic mouse models treated with LP-184 Across 10 TNBC PDX mouse models (All 10 TNBC PDX models - CTG-1522 and CTG-1643 models showed were HR deficient) LP-184 treatment resulted in a tumor growth i
Slide 24: Clinical Trial – Completed LP-184 Phase 1a Basket Trial
Clinical Trial – Completed LP-184 Phase 1a Basket Trial Potential blockbuster molecule with a market of $10+ billion in annual sales First-In-Human Trial for LP-184 63 $10+ Bn Clinicaltrials.gov (NCT05933265) Patients enrolled Achieved all primary endpoints with robust safety profile and promising a
Slide 25: Phase 1b/2 Biomarker Driven Trial of LP-184 in Advanced Urothelial Carcinoma
A Phase 1b/2 Biomarker Driven Trial of LP-184 in Advanced Urothelial Carcinoma (Bladder) with PTGR1-Positive and TC-NER/HR Deficient Single agent, starting dose = 0.39 mg/kg Dose de-escalation LP-184 D1,8 (21d) Phase 1b Determine the optimal LP-184 dose 3+3 (total n=3~18) Simon first stage (n=13) If
Slide 26: Phase 2 Trial of LP-184 Combination with PARPi in TNBC
A Phase 2 Trial of LP-184 Combination with PARPi in TNBC Clinical Study Schema NASDAQ: LTRN 25
Slide 27: LP-184 + Olaparib Combination Achieves 3-14x Greater Tumor Regression
LP-184 + Olaparib Combination Achieves 3-14x Greater Tumor Regression Compared To Olaparib Alone In TNBC PDX Models Tumor regression is achieved using 5x lower doses of LP-184 in combination as compared to doses used as monotherapy Vehicle LP-184 LP-184 LP-184 Olaparib Olaparib LP-184 LP-184 LP-184
Slide 28: LP-284 for the Treatment of B-cell Lymphomas and Soft Tissue Sarcomas
LP-284 for the Treatment of B-cell Lymphomas and Soft Tissue Sarcomas Mantle Cell, Double Hit Lymphomas, DDR Deficient Lead Indications Non-Hodgkin’s Lymphomas, Soft Tissue Sarcoma Phase 1 (Complete response in heavily pre-treated Clinical Status lymphoma patient) Market Potential* ~$6 Billion Indic
Slide 29: Disease Overview – B-cell NHL & Soft Tissue Sarcomas
Disease Overview – B-cell NHL & Soft Tissue Sarcomas LP-284 is being developed for aggressive cancers with significant unmet need and expanding market opportunity Annual Global Market Potential: ~$ 6 Billion (NHL + Adult Sot Tissue Sarcoma) B-cell Non-Hodgkin’s Lymphomas Soft Tissue Sarcomas 7th lea
Slide 30: Superior Responses to LP-284 are Observed Preclinically in Several NHLs
Superior Responses to LP-284 are Observed Preclinically in Several NHLs Including those Resistant to SOC Agents MCL tumor volumes drastically reduced compared Tumors resistant to Ibrutinib and Bortezomib has to FDA approved agents in mice models significantly reduced volume A. B. Nearly all MCL Pati
Slide 31: First-In-Human Trial for LP-284
LP-284 Highlights from NHL Clinical Trial & Potential New Indications Phase 1a trial for recurrent NHLs with scarce therapeutic options and potential in SLE / Lupus First-In-Human Trial for LP-284 Highlights • Heavily pretreated patient with aggressive LP-284 Received FDA Orphan Drug Grade 3 B-cell
Slide 32: Starlight Therapeutics Corporate Overview
Scan the QR code Devel oped f rom B i l l i ons for the full Starlight Corporate Overview of Data poi nts Usi ng A I $ 5-6 Bi l l i on M a r ket Potenti a l M ul ti pl e Cl i ni c a l Sta g e CN S Ca nc er Indi c ati ons Received Fast Track & Orphan Drug Designation for GBM, Orphan Drug & Rare Pedia
Slide 33: There Are Over 120 Types of CNS Cancers and a Majority Have No Curative Treatment Options
THERE ARE OVER 120 TYPES OF CNS CANCERS AND A MAJORITY HAVE NO CURATIVE TREATMENT OPTIONS Starlight’s Unique Areas of Focus Glioblastoma Brain Pediatric (GBM) Metastases CNS Cancers 13,000/yr in USA 100,000+/yr 4,000/yr in USA No effective systemic More effective therapies There are no approved thera
Slide 34: Origination of STAR-001 (LP-184): RADR Predictions Powered by AI
ORIGINATION OF STAR-001(LP-184): RADR PREDICTIONS POWERED BY AI Leading AI Technology developed by Lantern Pharma, RADR®, Helped Identify • PTGR1 levels correlate with drug response • Brain penetrant • GBM has higher levels of PTGR1 relative to normal brain • Novel alkylation site (at the N3 adenosi
Slide 35: STAR-001 Demonstrated Significant Tumor Reduction in Both Adult GBM and ATRT Mouse Models
STAR-001 Demonstrated A GBM Tumor volumes before and after STAR-001 treatment Significant Tumor Reduction in Both Adult GBM and ATRT Mouse Models STAR-001 STAR-001 N=3 per group N=3 per group B STAR-001 treatment of ATRT mouse tumors KEY TAKEAWAYS • STAR-001 reduced M1123 and U87 (GBM cell lines) tu
Slide 36: Research Suggests Increasing Investor and Industry Interest in CNS Oncology
RESEARCH SUGGESTS INCREASING INVESTOR AND INDUSTRY INTEREST IN CNS ONCOLOGY COMPANY VALUE TRANSACTION DATE STAGE COMPOUND INDICATION Acquired by April 21, PDUFA H3K27M Mutant 953 M Jazz Pharma 2025 After Phase II Trial Dordaviprone Gliomas Acquired by October TMZ-Resistant 1.3 B Merck 23, 2024 Precl
Slide 37: IP Portfolio
IP Portfolio Intellectual property portfolio builds expanding protections with additional barriers to competition 100 Pending Applications 5 Families 11 Families 2 Families + Issued Patents & Drug Sensitivity & Response Signatures using Biomarkers Methods of Use Composition of Matter RADR LP-300 LP-
Slide 38: Financial Highlights And Cap Table
Financial Highlights And Cap Table • Raised additional gross proceeds of up to $9.25M (approximately $4.4M in funding closed on May 14, 2026 and up to additional $4.85M of investor warrants at $2.27 per share exercise price) • Approx. $6.3M of cash, cash equivalents and marketable securities as of M
Slide 39: Leadership & Board of Directors
Leadership & Board of Directors Leadership PANNA SHARMA DAVID MARGRAVE KISHOR BHATIA, Ph.D. Chief Executive Officer & President Chief Financial Officer Chief Scientific Officer PRIOR: President & CEO, Cancer Genetics (CGIX); PRIOR: 20+ years of oncology focused PRIOR: 40+ years experience in cancer
Slide 40: 2026 Investment Highlights
2026 Investment Highlights Recent Milestones Upcoming Milestones & objectives Preliminary patient data showing an 86% clinical benefit rate in the initial safety lead-in cohort of the HarmonicTM Phase 2 Trial Complete further analysis of Phase 1a LP-184 results; pursue Phase 1b/2 and investigator or
Slide 41: IR Contact
IR Contact: IR@lanternpharma.com 1-972-277-1136 NASDAQ: LTRN www.lanternpharma.com CONNECT WITH US @LanternPharma linkedin.com/company/lanternpharma